Trial Purpose

This study is to evaluate the safety and efficacy of pembrolizumab/vibostolimab (MK-7684A) in combination with concurrent chemoradiotherapy (cCRT) followed by pembrolizumab/vibostolimab versus cCRT followed by durvalumab in participants with unresectable, locally advanced, stage III Non-small Cell Lung Cancer (NSCLC). The primary hypotheses are that pembrolizumab/vibostolimab with cCRT followed by pembrolizumab/vibostolimab is superior to cCRT followed by durvalumab with respect to the following:

progression free survival (PFS) per Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1 by blinded independent central review (BICR) in participants with programmed cell death ligand 1 (PD-L1) tumour proportion score (TPS) ≥1% and PD-L1 all comer participants.

overall survival (OS) in participants with PD-L1 TPS ≥1% and PD-L1 all comer participants.

View full trial information on Clinicaltrials.gov

NATIONAL TRIAL REFERENCE NUMBER

NCT05298423

EudraCT

2021-005135-23

When speaking to your doctor or clinical trial representative, please have the trial reference number available.

Resources

Eligibility

Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.

Conditions Icon

Conditions

Carcinoma, Non-Small-Cell Lung

Age Range Icon

Age Range

18+

Sex Icon

Sex

All

About The Trial

All patients who enroll in the trial will receive medication while on the study.

50% of patients will receive treatment with MK-7684A plus concurrent chemoradiotherapy (cCRT) followed by treatment with MK-7684A alone.

50% of patients will receive treatment with cCRT followed by treatment with durvalumab.

*You, your trial doctor, and the trial staff will know what you are getting.

Trial phase Icon Trial Phase

Trial Phase 3

Tests the medicine or vaccine in large groups of trial participants (from several hundred to several thousand). For medicines, volunteers have the disease or condition the medicine is designed to treat. In vaccine studies, the volunteers may be healthy or have diseases or conditions. Phase 3 trials take place in hospitals, clinics or doctors’ offices.

Trial start Icon Trial start and end dates
  • Actual study start date 3 May 2022
  • Estimated primary completion date 1 September 2028
  • Estimated study completion date 4 September 2029

Trial locations

Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.

What can you do next?

If you think this clinical trial might be a good fit and you are interested in taking part, take the next step to see if you are eligible.

Discuss with your doctor or care team

Print this page with details about the trial or email it to your doctor to discuss the clinical trial during your next visit.

Get help talking with your doctor or care team

NATIONAL TRIAL REFERENCE NUMBER

NCT05298423

EudraCT

2021-005135-23

When speaking to your doctor or clinical trial representative, please have the trial reference number available.

Taking part in a clinical trial is an important decision

If you are considering joining a clinical trial, first learn as much as you can about:

  • The investigational treatment that is being studied
  • What the risks and possible benefits are for participants

Talk to your doctor about the clinical trial before you decide to join.

Read our “What to Consider” page for more questions to ask and think about